Sequential treatment with bolus and continuous infusion of recombination factor VIIa for hip arthroplasty in a patient with haemophilia A and inhibitor

Haemophilia

Volumn 8, Issue 6, 2002, Pages 822-825

  Perez, R ^a   Martinez, M L ^a   Pinero A ^a   Sosa, R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Haemophilia A; Inhibitor; rFVIIa; Total hip replacement

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; CEFUROXIME; DICLOFENAC; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADULT; ARTICLE; BLOOD CLOTTING; BOLUS INJECTION; CASE REPORT; CONTINUOUS INFUSION; COST CONTROL; DOSE RESPONSE; DRUG USE; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HIP ARTHROPLASTY; HIP DISEASE; HOSPITAL DISCHARGE; HUMAN; MALE; PAIN; PHYSIOTHERAPY; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; THROMBOCYTE COUNT; WALKING AID;

EID: 0036861210     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00690.x     Document Type: Article

References (13)

1. Heeg M, Meyer K, Smid WM, Van Horn JR, Van der Meer J. Total knee and hip arthroplasty in haemophilic patients. Haemophilia 1998; 4: 747-51.
2. Lofqvist T, Sanzen L, Petersson C, Nilsson IM. Total hip replacement in patients with haemophilia. 13 hips in 11 patients followed for 1-16 years. Acta Orthop Scand 1996; 67 (4): 321-4.
3. Shapiro AD, Gilchrist GS, Hoots WK et al. Successful use of rFVIIa (Novoseven) in the treatment of inhibitor patients undergoing major or minor surgery. Thromb Haemost 1998; 80: 773.
4. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Sem Thromb Hemost 2000; 26 (4): 425-32.
5. Lusher JM. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Blood Coag Fibrinolysis 1998; 9 (Suppl. 1): S111-4.
6. Faradji A, Bonnomet F, Lecocq J et al. Knee joint arthrplasty in a patient with haemophilia ahd high inhibitor titre using recombinant factor VIIa (Novoseven®): a new case and review of the literature. Haemophilia 2001; 7: 321-6.
7. Schulman S, Bech Jensen M, Varon D, et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75 (3): 432-6.
8. Kenet G, Lubetsky A, Gite S, Luboshitz J, Varon D and Martinowitz U. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocol with recombinant activated factor VII. Blood Coagul Fibrinol Suppl 2000; 11(1): S35-S38.
9. Smith MP, Ludlam CA, Collins PW, Savidge GF. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII. Plasma factor VII activity 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86 (4): 949-53.
10. Goudemand J, Marey A, Renom P et al. Two cases of total hip replacement performed under treatment with recombinant factor VIIa. Haemophilia 1998; 4: 140.
11. Tagariello G, De Biasi E, Gajo GB, Radossi P, Davoli PG, Traldi A. Recombinant FVIIa (Novoseven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases. Haemophilia 2000; 6: 581-3.
12. Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not? Thromb Haemost 2001; 86: 942-4.
13. Hedner U. Dosing and monitoring Novoseven® treatment. Haemostasis 1996; 26: 102-8.